XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Preferred Stock Series C [Member]
Preferred Stock Series D [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Preferred Stock Series E [Member]
Beginning balance, value at Dec. 31, 2019 $ 4 $ 2 $ 15,424 $ 12,456,989 $ (8,198,785) $ 4,273,634
Beginning balance, shares at Dec. 31, 2019 3,501 2,000 15,424,394      
Purchase of acquisition $ (164) 164
Purchase of acquisition (shares)     (164,375)        
Conversion of Series C Preferred stock $ (4) $ 13,598 (13,594)
Conversion of Series C Preferred stock (shares) (3,501)   13,597,984        
Conversion of Series D Preferred stock and accrued dividends $ (2) $ 4,136 159,421 163,555
Conversion of Series D Preferred stock and accrued dividends (shares)   (2,000) 4,135,815        
Conversion of Series D warrants $ 6,854 2,627,602 2,634,456
Conversion of Series D warrants (shares)     6,853,975        
Issuance of Series E Preferred stock, net of issuance costs 1,009,999 1,010,000 $ 1
Issuance of Series E Preferred Stock, net of issuance costs, shares             1,050
Repurchase of Series E Preferred stock (1,110,880) (1,110,880)
Repurchase of Series E Preferred stock, Shares             (262)
Conversion of Series E Preferred stock $ 3,152 (3,151) $ (1)
Conversion of Series E Preferred stock (shares)     3,152,000       (788)
Deemed dividend on Series C Preferred stock and Series D warrants 4,050,838 (4,050,838)
Deemed dividend on redemption of Series D Preferred stock 3,763,591 (3,763,591)
Sale of Common stock, net of issuance costs $ 10,163 22,786,579 22,796,742
Sale of Common stock, net of issuance costs (shares)     10,163,105        
Sale of Common stock from conversion of pre-paid warrants $ 3,260 7 3,267
Sale of Common stock from conversion of pre-paid warrants (shares)     3,260,377        
Issuance of Common stock for consulting services $ 250 297,250 297,500
Issuance of Common stock for consulting services (shares)     250,000        
Common stock issued upon exercise of options $ 1,038 46,362 47,400
Exercise of options (shares)     1,037,727        
Stock-based compensation expense $ 170 264,218 264,388
Net loss (2,237,248) (2,237,248)
Stock-based compensation expense (shares)     170,000        
Ending balance, value at Sep. 30, 2020 $ 57,881 46,335,395 (18,250,461) 28,142,815
Ending balance, shares at Sep. 30, 2020 57,881,002      
Beginning balance, value at Jun. 30, 2020 $ 48,979 33,637,610 (17,671,855) 16,014,734
Beginning balance, shares at Jun. 30, 2020 110 48,979,277      
Conversion of Series D Preferred stock and accrued dividends $ 636 (636)
Conversion of Series D Preferred stock and accrued dividends (shares)   (110) 635,815        
Sale of Common stock, net of issuance costs $ 3,356 9,896,644 9,900,000
Sale of Common stock, net of issuance costs (shares)     3,355,705        
Sales of Common stock from exercise of warrants $ 3,906 2,630,550 2,634,456
Sale of Common Stock from exercise of warrants, shares     3,906,236        
Common stock issued upon exercise of options $ 1,004 46,396 47,400
Exercise of options (shares)     1,003,969        
Stock-based compensation expense 124,831 124,831
Net loss (578,606) (578,606)
Ending balance, value at Sep. 30, 2020 $ 57,881 46,335,395 (18,250,461) 28,142,815
Ending balance, shares at Sep. 30, 2020 57,881,002      
Beginning balance, value at Dec. 31, 2020 $ 58,636 47,241,757 (20,945,664) 26,354,729  
Beginning balance, shares at Dec. 31, 2020   58,636,365        
Sale of Common stock, net of issuance costs $ 6,763 37,175,883 37,182,646  
Sale of Common stock, net of issuance costs (shares)     6,763,091        
Sales of Common stock from exercise of warrants $ 2,517 8,302,851 8,305,368  
Sale of Common Stock from exercise of warrants, shares     2,516,778        
Issuance of Common stock for acquisition of MicaSense $ 541 2,999,459 3,000,000  
Issuance of Common stock for acquisition of MicaSense, shares     540,541        
Issuance of Common stock for acquisition of Measure     $ 5,319 24,369,681 24,375,000  
Issuance of Common stock for acquisition of Measure, shares     5,319,145        
Stock issued in exchange for professional services $ 550 2,906,450 2,907,000  
Stock issued in exchange for professional services, shares     550,000        
Common stock issued upon exercise of options $ 488 112,680 113,168  
Exercise of options (shares)     487,876        
Stock-based compensation expense $ 476 3,320,205 3,320,681  
Net loss (11,379,604) (11,379,604)  
Stock-based compensation expense (shares)     475,568        
Ending balance, value at Sep. 30, 2021 $ 75,289 126,428,967 (32,325,268) 94,178,988  
Ending balance, shares at Sep. 30, 2021 75,289,364        
Beginning balance, value at Jun. 30, 2021 $ 74,669 123,377,671 (28,554,366) 94,897,974  
Beginning balance, shares at Jun. 30, 2021 74,668,560        
Sale of Common stock, net of issuance costs $ 435 2,221,107 2,221,542  
Sale of Common stock, net of issuance costs (shares)     434,777        
Common stock issued upon exercise of options $ 81 37,262 37,343  
Exercise of options (shares)     81,861        
Stock-based compensation expense $ 104 792,927 793,031  
Net loss (3,770,902) (3,770,902)  
Stock-based compensation expense (shares)     104,166        
Ending balance, value at Sep. 30, 2021 $ 75,289 $ 126,428,967 $ (32,325,268) $ 94,178,988  
Ending balance, shares at Sep. 30, 2021 75,289,364